Reasons for buying:
Market Cap: ₹87,556 Cr (Bluechip stock)
Debt to Equity: Zero
Return on Equity 5Y Avg: 23.14%
EPS - 5Y Growth: 28.16%
Price-earnings to growth (5Y): 1.41
5Y RoE Consistency - Sustained without losing 20% in any year
Buy date: 28-Jul-2022
Qty: 2 Price: ₹3786.45 Buy EPS: 111.52
Buy date: 07-Nov-2022
Qty: 2 Price: ₹3407 Buy EPS: 116.97
Divi's Laboratories is a specialty and generic drug manufacturing company. Most of the company's sales are generated in Europe, followed by North America, India, and Asia. Divi operates two segments: the first is Generic APIs and Nutraceuticals, and the second is Custom Synthesis of APIs, intermediates, and specialty ingredients for innovators. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
No comments:
Post a Comment